Antihypertensive medical composite

A composition and drug technology, applied in the field of pharmacy, can solve the problem of no recommended drugs for AT1 receptor antagonists

Inactive Publication Date: 2010-10-27
北京奥萨医药研究中心有限公司 +1
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The Seventh Report of the United States Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of Hypertension (

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Embodiment 1: preparation of pharmaceutical composition

[0064] prescription

[0065] Enalapril Maleate 5.0g

[0066] Irbesartan 150.0g

[0067] Folic acid 0.4g

[0068] Microcrystalline Cellulose 35.0g

[0069] Starch 45.0g

[0070] Carboxymethyl starch sodium 5.0g

[0071] 5% Povidone K-30 QS

[0072] Magnesium stearate QS

[0073] Made into 1000 pieces

[0074] Preparation Process:

[0075] (1) Get the enalapril maleate, irbesartan, and folic acid of the prescribed amount, pass through a 100-mesh sieve, and mix them uniformly by the method of equal increments for subsequent use;

[0076] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0077] (3) Mix the starch, microcrystalline cellulose, carboxymethyl starch sodium according to the prescription amount and then mix evenly with the mixed raw material drug in equal increments;

[0078] (4) Add an appropriate amount of binder to make so...

Embodiment 2

[0080] Embodiment 2: pharmaceutical composition preparation

[0081] prescription

[0082] Enalapril Maleate 5.0g

[0083] Irbesartan 150.0g

[0084] Folic acid 0.8g

[0085] Microcrystalline Cellulose 35.0g

[0086] Starch 45.0g

[0087]Carboxymethyl starch sodium 5.0g

[0088] 5% Povidone K-30 QS

[0089] Magnesium stearate QS

[0090]

[0091] Made into 1000 pieces

[0092] Preparation Process:

[0093] (1) Get the enalapril maleate, irbesartan, and folic acid of the prescribed amount, pass through a 100-mesh sieve, and mix them uniformly by the method of equal increments for subsequent use;

[0094] (2) Other auxiliary materials are passed through a 100-mesh sieve and dried at 75°C for 2 hours;

[0095] (3) Mix the starch, microcrystalline cellulose, carboxymethyl starch sodium according to the prescription amount and then mix evenly with the mixed raw material drug in equal increments;

[0096] (4) Add an ap...

Embodiment 3

[0098] Embodiment 3: preparation of pharmaceutical composition

[0099] prescription

[0100] Fosinopril 10.0g

[0101] Valsartan 80.0g

[0102] Calcium Leucovorin 5.0g

[0103] Starch 20.0g

[0104] Microcrystalline Cellulose 15.0g

[0105] Carboxymethyl starch sodium 5.0g

[0106] Lactose 30.0g

[0107] Magnesium stearate QS

[0108]

[0109] Make 1000 capsules

[0110] Preparation Process:

[0111] According to the prescription ratio, take lactose, microcrystalline cellulose, starch, and carboxymethyl starch sodium and dry them at about 100°C for about 2 hours respectively, and pass through a 100-mesh sieve; after passing the raw material through a 100-mesh sieve, add the above-mentioned excipients in equal amounts Mix evenly and fill with No. 3 capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an antihypertensive medical composite which is composed of 0.5-100mg of angiotensin converting enzyme inhibitor with curative dose, 4-800mg of AT1 receptor antagonist, 0.1-50mg of one or more of B-complex vitamins and pharmaceutically acceptable carrier in one tablet. The invention has the advantages that the medical composite can increase the curative effect of the antihypertensive medicine, improve the target organ protection function of the medicine and reduce the incidence rate of complications such as fundus hemorrhage, angina pectoris, myocardial infarction, brain stroke, heart failure and kidney failure. In addition, the antihypertensive medical composite can be used to ensure the patient to take the medicine conveniently and reduce medical expenses.

Description

technical field [0001] The invention relates to a pharmaceutical composition for preventing, treating and delaying hypertension and related diseases, especially a pharmaceutical composition containing an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist and B vitamins . The present invention belongs to the field of pharmacy. Background technique [0002] Hypertension is currently the most prevalent cardiovascular disease, and it is also the main factor leading to coronary heart disease, stroke, congestive heart failure and renal dysfunction. Its morbidity and mortality have surpassed tumor diseases and ranked first. The prevalence rate of hypertension in my country is 27.2%, and there are more than 130 million patients at present, and the prevalence rate of hypertension is increasing rapidly. The main purpose of treating hypertensive patients is to minimize the total risk of cardiovascular death and disability. Drugs to lower blood pressure can...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/06A61P3/10A61P9/04A61P9/10A61P9/12A61P13/12
Inventor 陈光亮于多徐希平
Owner 北京奥萨医药研究中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap